Reactive oxygen species (ROS) are transient, highly reactive intermediates or byproducts produced during oxygen metabolism. However, when innate mechanisms are unable to cope with sequestration of surplus ROS, oxidative stress results, in which excess ROS damage biomolecules. Oxidized phosphatidylserine (PS), a proapoptotic 'eat me' signal, is produced in response to elevated ROS, yet little is known regarding its chemical composition and metabolism. Here, we report a small molecule that generates ROS in different mammalian cells. We used this molecule to detect, characterize and study oxidized PS in mammalian cells. We developed a chemical-genetic screen to identify enzymes that regulate oxidized PS in mammalian cells and found that the lipase ABHD12 hydrolyzes oxidized PS. We validated these findings in different physiological settings including primary peritoneal macrophages and brains from Abhd12 -/mice under inflammatory stress, and in the process, we functionally annotated an enzyme regulating oxidized PS in vivo.
O xidative stress is an imbalance between cellular oxidants and antioxidants in favor of oxidants, which leads to the disruption of redox signaling and has been implicated in several human pathophysiologies [1] [2] [3] [4] . Under oxidative stress, excess ROS, namely superoxide, hydrogen peroxide (H 2 O 2 ) and hydroxyl radicals, cannot be detoxified through innate coping mechanisms 5 , and consequently damage cellular components and cause cell death via apoptosis or necrosis 5 . Lipid membranes serve as cells' first line of defense against ROS by providing a physical barrier to ROS diffusion; therefore, membranes are primary targets for oxidative damage 5 . When ROS are generated near cellular membranes, the constituent lipids, particularly those bearing polyunsaturated fatty acid (PUFA) chains, are oxidized 6, 7 . The resulting oxidized lipids disrupt the local membrane structure and integrity, and thus impair cellular functions by modulating the activity of a wide array of important cellular proteins 8, 9 . Previously, research groups have focused on the oxidation of a single PUFA 6, 7 , but little is known regarding the global lipid profile under oxidative stress 8, 9 and the enzymatic pathways that metabolize those oxidized lipid products in vivo.
PS, a phospholipid localized to the inner-membrane leaflet, has several critical functions in mammalian biology 10 . Important among these is its role in ROS signaling and apoptosis 11 . Given the asymmetric distribution of PS in the membrane bilayer, the externalization of PS reflects a stressed cell, and this 'flipped' PS is recognized by phagocytes as an 'eat me' signal [12] [13] [14] . Several studies have suggested that under oxidative stress, surplus ROS reacts with the sn-2-esterified PUFAs of PS, thus producing oxidized PS 6 , which has a flipped membrane orientation; the oxidized PS then acts as an apoptotic signal 12, 14 . Although these studies have described the production and role of oxidized PS in apoptosis, little is known regarding its metabolism. Physiologically, this metabolism is important, because several cells require high oxygen tension (for example, neurons, macrophages and cancer cells) and consequently have elevated ROS, which produce oxidized PS in a constant flux. However, innate mechanisms within such cells can efficiently metabolize oxidized PS and prevent apoptosis.
In this paper, we synthesized and characterized a small molecule that generates ROS efficiently in mammalian cells and developed mass spectrometry methods to study oxidized PS; using both in tandem, we performed a chemical-genetic screen to identify lipases capable of metabolizing oxidized PS. We found that the serine hydrolase (SH) enzyme ABHD12 (α /β hydrolase domain (ABHD) protein 12) is a major oxidized-PS lipase. We validated these findings through complementary biochemical, pharmacological and genetic assays in different physiological systems. Importantly, we found that ABHD12 controls levels of oxidized PS in the mammalian brain under severe inflammatory stress. Given the central role of ABHD12 in the human neurological disease polyneuropathy, hearing loss, ataxia, retinitis pigmentosa and cataract (PHARC) 15, 16 , its role in metabolizing oxidized PS adds another avenue toward understanding the PHARC pathophysiology. (JCHD) 17 , with an esterase-activated handle ( Fig. 1a ). We postulated that MGR1 would be activated by the ubiquitous esterases 20 in mammalian cells and produce ROS ( Supplementary Fig. 1 ). To control for any structural effects of MGR1, we also synthesized a structural analog, MGR2 (2 ) , which has a naphthalene moiety and is unable to produce ROS ( Fig. 1a ). To validate the ROS-production abilities of MGR1 and MGR2, we first performed a chemiluminescence assay 21 and found that MGR1 but not MGR2 robustly produced ROS only when acted upon by an esterase (Fig. 1b ). In agreement with the proposed mechanism ( Supplementary Fig. 1 ), we found that pretreatment or incubation with a broad-spectrum SH inhibitor (fluorophosphonate (FP)-alkyne) 20 or superoxide dismutase (SOD), respectively, ablated the ROS-generating ability of MGR1 in vitro ( Supplementary Fig. 2 ). Next, we detected 2-hydroxyethidium (2-HE) from hydroethidine, owing to superoxide from MGR1 only in the presence of esterase, by high-performance liquid chromatography (HPLC) 22 (Fig. 1c ). SOD prevented 2-HE formation from MGR1 in the presence of an esterase, in agreement with superoxide formation from MGR1 after esterase activation ( Fig. 1c ). We also confirmed by HPLC analysis, that after esterase activity, MGR1 and MGR2 produced JCHD and 1-naphthol, respectively ( Supplementary Fig. 3 ). Next, we compared the ROS-producing capability of MGR1 with those of MGR2, xenobiotics (menadione, artemisinin, cisplatin and paraquat) and ROS generators (JCHD, oxidized JCHD and H 2 O 2 ), by using luminol-based chemiluminescence assays ( Supplementary  Fig. 2 ) and a commercial 2′ ,7′ -dichlorodihydro-fluorescein diacetate (DCF) cellular ROS-detection assay ( Supplementary Fig. 4 ). We found from the chemiluminescence assays that esterase-treated MGR1 had in vitro superoxide production comparable to that of JCHD and significantly higher than that of any ROS generator and/ or xenobiotic tested at a comparable concentration ( Supplementary  Fig. 2 ). We then treated HEK293T cells with MGR1, MGR2, xenobiotics or ROS generators (25 μ M for 1 h (1 mM H 2 O 2 ), followed by 10 μ M DCF for 10 min), and imaged the cellular fluorescence due to ROS. We found that MGR1 but not MGR2 robustly produced ROS in HEK293T cells, and MGR1 was the best ROS generator, as compared with the other xenobiotics and/or ROS generators ( Fig. 1d and Supplementary Fig. 5 ). Additionally, our prodrug approach of using MGR1 instead of JCHD resulted in more ROS production at the same MGR1 and JCHD concentrations, owing to better MGR1 bioavailability ( Supplementary Fig. 5 ). Similar results were found from other mammalian cell lines ( Supplementary Fig. 5 ).
To determine whether the surplus ROS from MGR1 affected cellular viability, we assessed the MGR1 and MGR2 dose dependence on cell death in different mammalian cell lines. In HEK293T cells, we found concentration-dependent cell death after treatment with MGR1 (half-maximal inhibitory concentration (IC 50 ) ~5.7 ± 0.6 μ M (mean ± s.e.m.), but not MGR2 (IC 50 > 40 μ M) treatment ( Fig. 1e ). Similar results were seen in other mammalian cell lines ( Supplementary Fig. 6 ). To confirm that the cell death was ROS dependent, we pretreated mammalian cells with antioxidants, pterostilbene (PTS, 10 μ M) 23 or N-acetyl-cysteine (NAC, 1 mM) 24 , then treated the cells with MGR1 and assessed ROS production. We found that both PTS and NAC substantially decreased the cellular ROS after MGR1 treatment ( Supplementary Fig. 7) . Additionally, the cell death caused by MGR1 treatment in different mammalian cell lines was also rescued by PTS or NAC, thus further confirming that the lower cellular viability was due to surplus ROS from MGR1 ( Supplementary Fig. 8 ). In subsequent cellular studies, we required a concentration of MGR1 that produced elevated ROS but was not high enough to cause cell death, and chose 2 μ M MGR1 or MGR2 (4 h) as the treatment paradigm ( Fig. 1e and Supplementary Fig. 6 ).
A quinone (JCHD) is produced from MGR1, and quinones are known to form covalent adducts with protein thiols 25, 26 . To determine the thiol reactivity of MGR1 relative to reactive quinones, we performed gel-based chemoproteomics, using iodoacetamidealkyne (IAA) as an activity reporter of cellular thiols 27 . In this experiment, HEK293T and RAW264.7 cell lysates were treated with the reactive quinones or MGR1 (+ esterase) (all 100 μ M, 1 h) and chased with IAA (1 mM, 1 h), after which click reaction was performed 28 , and the proteome was resolved and visualized on an SDS-PAGE gel. We found negligible proteome-wide thiol reactivity for MGR1 (or JCHD) relative to reactive quinones ( Fig. 1f ). Mass spectrometry-based chemoproteomics further confirmed the negligible proteome-wide thiol and serine reactivity of MGR1 (2 μ M, 4 h) in HEK293T cells (Supplementary Figs. 9-12 and Supplementary Dataset 1), thus suggesting that the cell death caused by MGR1 was due to surplus ROS and not thiol modification by the quinone product.
Measurement of oxidized PS in cells.
Our interest in understanding oxidized-PS metabolism under oxidative stress stemmed from its importance in programmed cell death 12 , and we decided to establish an LC-MS/MS method to measure oxidized PS. We first treated C18:0/18:1 PS (1-stearoyl-2-oleoyl-sn-glycero-3-phospho-l-serine, 100 μ g) with excess H 2 O 2 (10 mM) in the presence of iron(ii) (1 mM) and ascorbate (1 mM) to produce ROS through Fenton and Haber-Weiss chemistry 29 . We found that, in addition to the native mass of 788.5445 ([M -H]: C18:0/18:1 PS), two new masses of 804.5392 and 806.5549 were present ( Fig. 2a ). We performed MS/MS on these masses and found that 804.5392 and 806.5549 were + 16 (O) and + 18 (H 2 O) additions, respectively. The MS/ MS fragmentations for both these masses suggested that mass additions of + 16 (m/z = 297.2431) and + 18 (m/z = 299.2590) were present on the sn-2 oleate of C18:0/18:1 PS, forming an epoxide and a hydroxide, respectively ( Fig. 2a , Supplementary Fig. 13 and Supplementary Note). We denoted the + 16 and + 18 mass additions with the prefixes ox-and hy-, respectively. We hypothesized that the oxygenation of C18:0/18:1 PS would increase its hydrophilicity, and the resulting oxygenated species would elute earlier on a C18 column. Our observations supported our hypothesis: ox-18:0/18:1 PS and hy-18:0/18:1 PS eluted at 27.8 and 27.1 min, respectively, whereas C18:0/18:1 PS eluted at 32.3 min with our LC-MS/MS method 30 (Fig. 2b ). C18:1 lyso-PS eluted at 24.9 min, thus suggesting that both ox-18:0/18:1 PS and hy-18:0/18:1 PS were more lipophilic than C18:1 lyso-PS, because of an additional fatty acid ( Fig. 2b ). Corroborating the LC-MS/MS findings, thin layer chromatography (TLC) 31 showed a distinct spot for oxidized PS between PS and lyso-PS ( Supplementary Fig. 14) .
To determine whether MGR1 produces oxidized PS, we treated HEK293T cells with MGR1, MGR2 or DMSO (2 μ M, 4 h), and extracted the phospholipids 30, 32 . We detected m/z = 788.5445 in all treatment groups, but m/z = 804.5392 and 806.5549 were enriched after MGR1 treatment. To determine whether these masses corresponded to C18:0/18:1 PS, or the synthetic ox-18:0/18:1 PS and hy-18:0/18:1 PS, we performed MS/MS analysis on endogenous m/z = 788.5445, 804.5392 and 806.5549 from phospholipids extracted from MGR1-treated cells. We found that the MS/MS fragmentations for the endogenous masses exactly matched the synthetic standards. Notably, all three masses showed peaks at the parent m/z minus 87.0315 (loss of serine), 437.2671 (1-stearoyl-2-hydroxy-sn-glycero-3-phosphate), 419.2562 (dehydro-1-stearoyl-2-hydroxy-sn-glycero-3-phosphate), 283.2640 (stearate) and 152.9951 (dehydro-glycerophosphate) ( Fig. 2a ). We also detected m/z = 297.2433 and 299.2590 in the MS/MS fragmentations of endogenous 804.5392 and 806.5549, respectively, thus confirming the formation of + 16 (epoxy) and + 18 (hydroxide) oxygenated adducts described earlier for ox-18:0/18:1 PS and hy-18:0/18:1 PS, respectively ( Fig. 2a ).
The MS/MS fragmentation helped us to develop a targeted multiple reaction monitoring high-resolution (MRM-HR) LC-MS/MS method to quantify different oxidized-PS species (Supplementary Dataset 2). We validated this method by quantifying ox-18:0/18:1 PS and hy-18:0/18:1 PS from HEK293T cells treated with MGR1, MGR2 or DMSO (2 μ M, 4 h), and we found that the MGR1-treated cells had substantially more ox-18:0/18:1 PS and hy-18:0/18:1 PS than MGR2-or DMSO-treated cells, and showed similar elution times to the synthetic standards ( Fig. 2c and Supplementary  Fig. 13 ). Next, we measured different ox-and hy-PS after MGR1 and MGR2 treatments in HEK293T cells and found that several ox-PS and hy-PS were significantly elevated after treatment with MGR1 but not MGR2 or DMSO (Fig. 2d) . Notably, all detected oxidized PS bore an unsaturated fatty acid esterified at the sn-2 position, where the oxygenation probably occurs. We found no changes in cellular PS or lyso-PS, and we were unable to detect oxidized PS secreted from HEK293T cells after treatment with MGR1 or MGR2 (Supplementary Dataset 2). Similar results were observed in other mammalian cell lines ( Supplementary Fig. 15 and Supplementary Dataset 2).
Chemical-genetic screen to identify oxidized-PS lipases. To better understand oxidized-PS metabolism, we developed a screen to identify enzymes that hydrolyze oxidized-PS lipids, by using the aforementioned LC-MS/MS method. At the onset, we hypothesized that a lipase (probably a metabolic SH) would perform this activity 20, 33 . Hence, we needed a cell line that expresses many SHs and has high lipid content for our screen. Because public databases 34 have shown that RAW264.7 macrophages fulfill these criteria, we chose this cell line as the candidate for the screen. We collated a focused library of 57 compounds, ranging from specific to broad-spectrum lipase inhibitors 20, 33 (Supplementary Dataset 3) . We treated RAW264.7 cells with inhibitor (10 μ M, 4 h) followed by MGR1 (5 μ M, 4 h), after which we extracted cellular phospholipids and analyzed the oxidized PS with targeted LC-MS/MS ( Supplementary  Fig. 16 ). We used MGR2 and DMSO as screening controls. We set twofold accumulation in cellular oxidized PS as the threshold for identifying hits from the screen, and we found that most inhibitors had no effect on oxidized PS (effects comparable to those of DMSO after MGR1 treatment). However, three compounds-FP-alkyne, tetrahydrolipstatin (THL, also known as orlistat) and methylarachidonyl fluorophosphonate (MAFP)-showed an increase of more than twofold in cellular oxidized PS ( Fig. 3a ). Both FP-alkyne and MAFP are broad-spectrum SH inhibitors 20 , thus further confirming that the lipase of interest was an SH. Because FP-alkyne and MAFP have several enzyme targets, we focused on THL, because this β -lactone inhibitor potently inhibits only a few SHs 35 .
To determine targets of THL in RAW264.7 cells, we used competitive-activity-based protein profiling (ABPP) assays. We treated RAW264.7 cells with THL (10 μ M, 4 h), then assessed the membrane and soluble proteomes through competitive gel-based ABPP 32 ( Fig. 3b and Supplementary Fig. 17 ). After THL treatment, we found no activity loss in the soluble proteome, whereas the membrane proteome showed several enzymes whose activity was inhibited. Prominent among these was a SH of ~42 kDa, probably ABHD12, a known THL target 35 (Fig. 3b and Supplementary Fig. 17 ). Next, we coupled ABPP (by using a biotinylated FP probe, FP-biotin) 36 to LC-MS/MS analysis 32 , and identified 34 SHs, of which 12 were inhibited > 90% (THL, 10 μ M, 4 h). Not surprisingly, there were seven lipases (ABHD6, neuropathy target esterase (PNPLA6), hormone-sensitive lipase (HSL or LIPE), ABHD16A, patatin-like phospholipase domain containing protein 7 (PNPLA7), cytosolic phospholipase A2 (PLA2G4A) and ABHD12) among these targets ( Fig. 3c and Supplementary Dataset 4). In addition to these, diacylglycerol lipase beta (DAGLβ ) and lipoprotein-associated phospholipase A2 (PLA2G7) are also targets of THL 35 . We detected DAGLβ but unexpectedly did not observe substantial inhibition of DAGLβ (Supplementary Dataset 4). We did not detect PLA2G7 in our experiments. Our chemical-genetic screen included specific inhibitors for most THL targets, and these showed almost no effect on cellular oxidized PS in the screen (KT195, WWL70: ABHD6; palmostatin-B: PNPLA6; BAY, Cay10499: HSL; KC01: ABHD16A; pyrrophenone: PLA2G4A; KT109, KT172: DAGLβ ; and darapladib, JMN4: PLA2G7) ( Supplementary Dataset 3) . This procedure enabled the elimination of most lipase targets of THL, except ABHD12 and PNPLA7, thus suggesting that one of these lipases was likely to be an oxidized-PS lipase. Nonetheless, we overexpressed all the lipase targets of THL in HEK293T cells and tested these lysates for substrate hydrolysis activity against lyso-PS, oxidized PS and PS. Additionally, we tested the SHs ABHD3 (ref. 37 ) and PNPLA8 (ref. 38 ), because they have been reported to hydrolyze oxidized phospholipids. We found that, among all candidate lipases, ABHD12 was the best candidate, with a hydrolysis rate for oxidized PS more than threefold higher than that of any other lipase ( Supplementary Fig. 18 ). As expected, ABHD12 had robust activity against lyso-PS but not PS 39 ( Supplementary Fig. 18 ), thus suggesting that this enzyme can use both lyso-PS and oxidized PS as substrates in vitro.
Biological validation of ABHD12 as an oxidized-PS lipase.
To validate whether ABHD12 was indeed an oxidized-PS lipase, we first generated the catalytically 'dead' S246A mutant of human ABHD12 (hABHD12), then overexpressed S246A hABHD12, wild type (WT) hABHD12 or an empty plasmid (mock) in HEK293T cells. Western blot analysis confirmed that WT hABHD12 and S246A hABHD12 were overexpressed in HEK293T membranes, and gel-based ABPP confirmed that S246A hABHD12 was inactive (Fig. 4a ). We also confirmed that WT hABHD12 was potently inhibited by THL 35 ( Supplementary Fig. 19 ). First, membrane lysates from HEK293T cells overexpressing mock, WT hABHD12 or S246A hABHD12 were tested against lyso-PS, oxidized PS or PS; 32, 39 we found that WT hABHD12 efficiently hydrolyzed lyso-PS and oxidized PS at (Fig. 4b) . S246A hABHD12 and mock HEK293T membrane lysates had negligible activity against all three substrates (Fig. 4b ). Next, we tested whether heightened ABHD12 activity had any effect on cell viability after MGR1 treatment. Here, HEK293T cells with mock, WT hABHD12 or S246A hABHD12 transfection were treated with MGR1 (0-40 μ M, 4 h), and the viable cells were quantified. We found that the mock (IC 50 = 1.7 ± 0.6 μ M) and S246A hABHD12 (IC 50 = 1.9 ± 0.4 μ M) cells had comparable cell-viability profiles after MGR1 treatment, whereas the increased activity of WT hABHD12 partly protected against MGR1 treatment (IC 50 = 13.9 ± 2.4 μ M) ( Fig. 4c ).
Furthermore, we tested whether overexpression of WT hABHD12 had any effect on cellular oxidized PS. Here, HEK293T cells with mock, WT hABHD12 or S246A hABHD12 transfection were treated with MGR1 (2 μ M, 4 h), and cellular oxidized PS was quantified. We found that cells overexpressing WT hABHD12 had significantly lower cellular oxidized PS than did mock-or S246A hABHD12-overexpressing cells ( Fig. 4d and Supplementary Dataset 2), in agreement with the ability of WT hABHD12 but not S246A hABHD12 to hydrolyze oxidized PS. Finally, we tested whether the pharmacological blockade of ABHD12 might have any effect on cellular oxidized PS. In the absence of any reported ABHD12 selective cell active inhibitor, we treated RAW264.7 cells with increasing THL (0-10 μ M, 4 h) and found a dose-dependent increase in oxidized PS after THL treatment ( Fig. 4e and Supplementary Dataset 2) . This result suggests that acute blockade of ABHD12 activity controls cellular oxidized PS.
ABHD12 functions as an oxidized-PS lipase in vivo.
To physiologically complement our studies, we first investigated oxidized PS from primary peritoneal macrophages (PPMs) harvested from WT or ABHD12-knockout mice. We found that lipopolysaccharide (LPS) stimulation of PPMs increased the cellular ROS and lyso-PS levels, and ABHD12 controls secreted lyso-PS ( Supplementary  Figs. 20 and 21 and Supplementary Dataset 2) , as previously reported 32, 40 . Interestingly, PPMs from WT mice, showed a twofold increase in cellular oxidized PS after LPS stimulation, thus corroborating the increased cellular ROS in PPMs after LPS stimulation 40 (Fig. 5a and Supplementary Dataset 2) . Notably, after both vehicle and LPS treatments, PPMs from ABHD12-knockout mice always had approximately twofold more cellular oxidized PS than PPMs from WT mice ( Fig. 5a and Supplementary Dataset 2). We did not detect any oxidized-PS secretion from PPMs from either genotype. Next, we tested whether the oxidized PS that we identified might have any role in immunological activation. To assess this possibility, we incubated PPMs from WT or ABHD12-knockout mice with freshly prepared oxidized PS (mixture of ox-18:0/18:1 PS and hy-18:0/18:1 PS), or C18:0/18:1 PS, C18:1 lyso-PS or LPS (all 10 μ g/mL, 4 h), then measured the proinflammatory-cytokine secretion from these cells. We found that oxidized PS produced ten-and fivefold more secretion of the cytokines TNF-α and IL-6 in WT PPMs than in the vehicle (or C18:0/18:1 PS) and lyso-PS Supplementary Fig. 26 . b, Substrate assays of membrane proteomes from HEK293T cells with mock, WT or S246A hABHD12 transfection, showing robust hydrolysis of lyso-PS (C18:1) and oxidized PS (ox-C18:0/18:1 PS + hy-18:0/18:1 PS) by the WT but not the S246A hABHD12 or mock proteomes. All proteomes showed negligible activity for the C18:0/18:1 PS. The data represent mean ± s.e.m. for 3 independent experiments. c, Cell viability assays on HEK293T cells with mock, WT or S246A hABHD12 transfection, which were treated with increasing concentrations of MGR1 (0-40 μ M, 4 h). The results show greater cellular viability for WT hABHD12-transfected HEK293T cells after MGR1 treatment than for mock-or S246A hABHD12-transfected HEK293T cells. Data represent mean ± s.e.m. for 4 independent experiments, and the 95% confidence intervals for the reported IC 50 values of MGR1 for the mock, WT and S246A groups were 1.5-2.3, 11.5-16. Previous studies in a mouse model for PHARC have shown that ABHD12 regulates levels of lyso-PS in the mammalian brain and immune system 32, 39 , and hence lyso-PS has been attributed to the neuroinflammatory and neurobehavioral disturbances seen in human patients with PHARC 39 . Here, we show that ABHD12 also controls the levels of oxidized PS in different mammalian systems, including primary mouse macrophages and the brain, under oxidative stress. On the basis of previous immunological studies, which suggest a role of oxidized PS in cellular apoptosis, we add to the existing model describing the pathology of PHARC: oxidized PS produced from surplus ROS during oxidative stress may, together with lyso-PS, contribute synergistically to the pathology of this neurological disorder. GPS, glycerophosphoserine; FFA, free fatty acid.
control groups, respectively, and approximately half that in the LPS group (Fig. 5b) . When comparing the WT and ABHD12knockout groups, we found that across all treatments, the PPMs from ABHD12-knockout mice always secreted more TNF-α and IL-6. Notably, oxidized-PS treatment of PPMs from ABHD12knockout mice showed the greatest response, with approximately twofold greater TNF-α and IL-6 secretion than that of WT PPMs (Fig. 5b ). We observed similarly increased proinflammatory-cytokine secretion after oxidized-PS treatment in THP1 macrophages ( Supplementary Fig. 22 ), thus suggesting that oxidized PS is a more potent immunostimulatory lipid than lyso-PS or PS.
Finally, we attempted to analyze oxidized PS in the brains of WT and ABHD12-knockout mice, but were unable to detect it in either genotype. Therefore, we induced neuroinflammation in these mice through intraperitoneal LPS injections with two paradigms 41 -high-dose acute (20 mg/kg, 6 h) and low-dose chronic (1 mg/kg daily for 4 d)-to determine whether oxidized PS was produced, given that these neuroinflammatory LPS stimuli are known to generate enhanced ROS in the mammalian brain 42, 43 . We confirmed that the neuroinflammatory challenges were effective by measuring increased prostaglandin and proinflammatory cytokines in the brains of the LPS-treated mice ( Supplementary Fig. 23 ). Interestingly, we found that mice given the the low-dose chronic treatment showed negligible accumulation of oxidized PS, but mice given the high-dose acute treatment showed significant accumulation of oxidized PS in the brain ( Fig. 5c and Supplementary Dataset 2). The oxidized-PS accumulation between these genotypes was most pronounced for the high-dose acute treatment, under which the ABHD12-knockout brains accumulated oxidized PS to levels more than fivefold greater than those in similarly treated WT mice (Fig. 5c ). We found that the ABHD12-knockout mouse brains always had higher brain lyso-PS content than that in similarly treated WT mouse brains, but the lyso-PS levels did not change during the LPS treatments ( Supplementary Fig. 24 and Supplementary Dataset 2). Interestingly, proinflammatory cytokines were also significantly elevated in the ABHD12-knockout brains after high-dose acute LPS treatments ( Supplementary Fig. 23 ).
Discussion
The oxidation of PS due to elevated ROS is linked to its transmembrane migration and presence on the exofacial membrane surface 14, 44 (Supplementary Fig. 25 ), where oxidized-PS externalization generates an 'eat me' signal enabling recognition by phagocytes 12 . An elegant study has shown that apoptotic cells are indeed cleared by macrophages, through specific recognition of externalized oxidized PS by a B-type scavenger receptor 13 . Additionally, the cellular protein annexin-V binds externalized oxidized PS, and several kits for this protein-lipid interaction are available to quantitatively measure apoptotic cells. Whereas PS oxidation and its role in apoptosis are well understood, little is known regarding the enzymatic pathways that metabolize oxidized PS in vivo.
In this study, we sought to identify an enzyme capable of metabolizing oxidized PS in mammalian cells. To this end, we synthesized a chemical probe capable of robustly generating ROS in mammalian cells, thus enabling us to mimic oxidative stress (Fig. 1 ). Next, we developed an LC-MS/MS method to identify and quantify oxidized PS in mammalian cells, and detected two new oxidized-PS species, termed ox-PS and hy-PS, in different mammalian cells in response to oxidative stress (Fig. 2) . We performed a chemical-genetic screen to identify an enzyme capable of metabolizing oxidized PS in mammalian cells and identified ABHD12 as a likely candidate (Fig. 3) . We provide compelling biochemical, pharmacological and genetic evidence suggesting that ABHD12 is a major lipase capable of hydrolyzing oxidized PS (Figs 4 and 5 ).
ABHD12 is of tremendous biomedical interest because it is associated with the human neurodegenerative disease PHARC, which is caused by null mutations to ABHD12 (refs. 15, 16 ). ABHD12 is annotated as a lyso-PS lipase in the mammalian brain and immune system 16, 32, 39, 45 . Lipidomic analysis of PPMs from ABHD12-knockout mice 39 and PHARC lymphoblasts from human subjects 16 has indicated that ABHD12 controls levels of secreted lyso-PS but not cellular lyso-PS 32 . This result is not surprising, because the active site of ABHD12 is extracellularly orientated 32, 45, 46 . It is this active site orientation that, we believe, allows it to access exofacially oriented oxidized PS generated by elevated cellular ROS during oxidative stress ( Supplementary Fig. 25 ). Our studies thus suggest a dual role for ABHD12, in which it regulates cellular oxidized PS and secreted lyso-PS, independently or simultaneously (for example, PPMs). We also found that the newly identified oxidized PS elicits immune responses in PPMs through heightened secretion of proinflammatory cytokines, and the responses are more pronounced in ABHD12null PPMs. Finally, we determined that ABHD12 controls the levels of oxidized PS in the mammalian brain and in turn the levels of proinflammatory cytokines under severe neuroinflammatory stimuli. Together, our studies build on the existing model describing the progression of PHARC pathology. We propose that, like other neurodegenerative disorders, oxidative stress and ROS may also play roles in PHARC pathology, and, in a basic model, ABHD12 mitigates excess oxidized PS produced in this process (Fig. 5d ).
Looking forward, we note that gene expression studies 34 have suggested that ABHD12 is expressed mostly in the nervous and immune systems, yet PS is known to exist in metabolic tissues susceptible to oxidative stress 11 . Hence, resident lipases beyond ABHD12 that metabolize oxidized PS in these tissues must exist. We believe that the tools and methods described here might offer an elegant strategy for functionally annotating such lipases. In addition, developing new tools that enable visualization of oxidized PS in vivo would be beneficial in understanding the spatiotemporal distribution and regulation of these lipids in diverse biological settings. Because the protein ligands and/or receptors for oxidized PS are largely unknown, finding and understanding downstream biological signaling pathways by using emerging chemoproteomics platforms 47, 48 would advance the lipid-signaling field and provide new insights into programmed cell death. Finally, recent functional studies have shown that other metabolic SHs are regulators of other oxidized phospholipids in vivo 49, 50 . We believe that the emerging functional annotation of orphan SHs might implicate their roles in regulating oxidized lipids from other lipid classes (for example, neutral lipids or sterols) and, in doing so, increase the repertoire of oxidized lipids under oxidative stress.
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